Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
You may also be interested in...
Angle PLC has published half year interim results which indicate it will capitalize on a new liquid biopsy market.
Following a successful fundraise, Angle is poised to further commercialize its proprietary cell-catching technology for cancer diagnosis
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.